10-Q 1 rviv-20220228_10q.htm 10-Q
0001718500 false --05-31 2022 Q3 P5Y P3Y P5Y P10Y 0001718500 2021-06-01 2022-02-28 0001718500 2022-04-11 0001718500 2022-02-28 0001718500 2021-05-31 0001718500 2021-12-01 2022-02-28 0001718500 2020-12-01 2021-02-28 0001718500 2020-06-01 2021-02-28 0001718500 us-gaap:PreferredStockMember 2021-05-31 0001718500 us-gaap:CommonStockMember 2021-05-31 0001718500 us-gaap:AdditionalPaidInCapitalMember 2021-05-31 0001718500 us-gaap:RetainedEarningsMember 2021-05-31 0001718500 us-gaap:PreferredStockMember 2021-11-30 0001718500 us-gaap:CommonStockMember 2021-11-30 0001718500 us-gaap:AdditionalPaidInCapitalMember 2021-11-30 0001718500 us-gaap:RetainedEarningsMember 2021-11-30 0001718500 2021-11-30 0001718500 us-gaap:PreferredStockMember 2020-05-31 0001718500 us-gaap:CommonStockMember 2020-05-31 0001718500 us-gaap:AdditionalPaidInCapitalMember 2020-05-31 0001718500 us-gaap:RetainedEarningsMember 2020-05-31 0001718500 2020-05-31 0001718500 us-gaap:PreferredStockMember 2020-11-30 0001718500 us-gaap:CommonStockMember 2020-11-30 0001718500 us-gaap:AdditionalPaidInCapitalMember 2020-11-30 0001718500 us-gaap:RetainedEarningsMember 2020-11-30 0001718500 2020-11-30 0001718500 us-gaap:PreferredStockMember 2021-06-01 2022-02-28 0001718500 us-gaap:CommonStockMember 2021-06-01 2022-02-28 0001718500 us-gaap:AdditionalPaidInCapitalMember 2021-06-01 2022-02-28 0001718500 us-gaap:RetainedEarningsMember 2021-06-01 2022-02-28 0001718500 us-gaap:PreferredStockMember 2021-12-01 2022-02-28 0001718500 us-gaap:CommonStockMember 2021-12-01 2022-02-28 0001718500 us-gaap:AdditionalPaidInCapitalMember 2021-12-01 2022-02-28 0001718500 us-gaap:RetainedEarningsMember 2021-12-01 2022-02-28 0001718500 us-gaap:PreferredStockMember 2020-06-01 2021-02-28 0001718500 us-gaap:CommonStockMember 2020-06-01 2021-02-28 0001718500 us-gaap:AdditionalPaidInCapitalMember 2020-06-01 2021-02-28 0001718500 us-gaap:RetainedEarningsMember 2020-06-01 2021-02-28 0001718500 us-gaap:PreferredStockMember 2020-12-01 2021-02-28 0001718500 us-gaap:CommonStockMember 2020-12-01 2021-02-28 0001718500 us-gaap:AdditionalPaidInCapitalMember 2020-12-01 2021-02-28 0001718500 us-gaap:RetainedEarningsMember 2020-12-01 2021-02-28 0001718500 us-gaap:CommonStockMember 2020-11-01 2021-02-28 0001718500 us-gaap:PreferredStockMember 2022-02-28 0001718500 us-gaap:CommonStockMember 2022-02-28 0001718500 us-gaap:AdditionalPaidInCapitalMember 2022-02-28 0001718500 us-gaap:RetainedEarningsMember 2022-02-28 0001718500 us-gaap:PreferredStockMember 2021-02-28 0001718500 us-gaap:CommonStockMember 2021-02-28 0001718500 us-gaap:AdditionalPaidInCapitalMember 2021-02-28 0001718500 us-gaap:RetainedEarningsMember 2021-02-28 0001718500 2021-02-28 0001718500 rviv:CustomerMember 2021-12-01 2022-02-28 0001718500 rviv:CustomerMember 2020-12-01 2021-02-28 0001718500 rviv:CustomerMember 2021-06-01 2022-02-28 0001718500 rviv:CustomerMember 2020-06-01 2021-02-28 0001718500 us-gaap:FurnitureAndFixturesMember 2022-02-28 0001718500 us-gaap:FurnitureAndFixturesMember 2021-05-31 0001718500 us-gaap:FurnitureAndFixturesMember 2021-06-01 2022-02-28 0001718500 us-gaap:ComputerEquipmentMember 2022-02-28 0001718500 us-gaap:ComputerEquipmentMember 2021-05-31 0001718500 us-gaap:ComputerEquipmentMember 2021-06-01 2022-02-28 0001718500 us-gaap:MachineryAndEquipmentMember srt:MinimumMember 2021-06-01 2022-02-28 0001718500 us-gaap:MachineryAndEquipmentMember srt:MaximumMember 2021-06-01 2022-02-28 0001718500 rviv:ConsultantMember 2021-12-01 2022-02-28 0001718500 rviv:ConsultantMember 2020-12-01 2021-02-28 0001718500 rviv:ConsultantMember 2021-06-01 2022-02-28 0001718500 rviv:ConsultantMember 2020-06-01 2021-02-28 0001718500 rviv:PaycheckProtectionProgram2Member 2022-02-28 0001718500 rviv:PaycheckProtectionProgram2Member 2021-05-31 0001718500 rviv:EconomicInjuryDisasterLoanProgramMember 2022-02-28 0001718500 rviv:EconomicInjuryDisasterLoanProgramMember 2021-05-31 0001718500 us-gaap:CommonStockMember rviv:Consultant1Member 2020-06-01 2021-02-28 0001718500 rviv:Consultant1Member 2020-06-01 2021-02-28 0001718500 us-gaap:CommonStockMember rviv:Consultant2Member 2020-06-01 2021-02-28 0001718500 rviv:Consultant2Member 2020-06-01 2021-02-28 0001718500 us-gaap:SalesRevenueNetMember 2021-12-01 2022-02-28 0001718500 us-gaap:SalesRevenueNetMember rviv:CustomerOneMember 2021-12-01 2022-02-28 0001718500 us-gaap:SalesRevenueNetMember 2021-06-01 2022-02-28 0001718500 us-gaap:SalesRevenueNetMember rviv:CustomerOneMember 2021-06-01 2022-02-28 0001718500 us-gaap:SalesRevenueNetMember rviv:CustomerTwoMember 2021-06-01 2022-02-28 0001718500 us-gaap:SalesRevenueNetMember 2020-12-01 2021-02-28 0001718500 us-gaap:SalesRevenueNetMember rviv:CustomerOneMember 2020-12-01 2021-02-28 0001718500 us-gaap:SalesRevenueNetMember 2020-06-01 2021-02-28 0001718500 us-gaap:SalesRevenueNetMember rviv:CustomerOneMember 2020-06-01 2021-02-28 0001718500 us-gaap:SalesRevenueNetMember rviv:CustomerTwoMember 2020-06-01 2021-02-28 0001718500 us-gaap:SalesRevenueNetMember us-gaap:NonUsMember 2021-12-01 2022-02-28 0001718500 us-gaap:SalesRevenueNetMember country:CA 2021-12-01 2022-02-28 0001718500 us-gaap:SalesRevenueNetMember us-gaap:NonUsMember 2021-06-01 2022-02-28 0001718500 us-gaap:SalesRevenueNetMember country:CA 2021-06-01 2022-02-28 0001718500 us-gaap:SalesRevenueNetMember us-gaap:EuropeanUnionMember 2021-06-01 2022-02-28 0001718500 us-gaap:SalesRevenueNetMember us-gaap:NonUsMember 2020-12-01 2021-02-28 0001718500 us-gaap:SalesRevenueNetMember country:CA 2020-12-01 2021-02-28 0001718500 us-gaap:SalesRevenueNetMember country:IT 2020-12-01 2021-02-28 0001718500 us-gaap:SalesRevenueNetMember country:GB 2020-12-01 2021-02-28 0001718500 us-gaap:SalesRevenueNetMember us-gaap:NonUsMember 2020-06-01 2021-02-28 0001718500 us-gaap:SalesRevenueNetMember country:CA 2020-06-01 2021-02-28 0001718500 us-gaap:SalesRevenueNetMember country:IT 2020-06-01 2021-02-28 0001718500 us-gaap:AccountsReceivableMember 2021-06-01 2022-02-28 0001718500 us-gaap:AccountsReceivableMember rviv:CustomerOneMember 2021-06-01 2022-02-28 0001718500 us-gaap:AccountsReceivableMember rviv:CustomerTwoMember 2021-06-01 2022-02-28 0001718500 us-gaap:AccountsReceivableMember rviv:CustomerThreeMember 2021-06-01 2022-02-28 0001718500 us-gaap:AccountsReceivableMember rviv:CustomerFourMember 2021-06-01 2022-02-28 0001718500 us-gaap:AccountsReceivableMember 2020-06-01 2021-05-31 0001718500 us-gaap:AccountsReceivableMember rviv:CustomerOneMember 2020-06-01 2021-05-31 0001718500 us-gaap:AccountsReceivableMember rviv:CustomerTwoMember 2020-06-01 2021-05-31 0001718500 us-gaap:AccountsReceivableMember rviv:CustomerThreeMember 2020-06-01 2021-05-31 0001718500 us-gaap:AccountsReceivableMember rviv:CustomerFourMember 2020-06-01 2021-05-31 0001718500 rviv:VendorsMember 2021-06-01 2022-02-28 0001718500 rviv:VendorsMember rviv:VendorOneMember 2021-06-01 2022-02-28 0001718500 rviv:VendorsMember rviv:VendorTwoMember 2021-06-01 2022-02-28 0001718500 rviv:VendorsMember rviv:VendorThreeMember 2021-06-01 2022-02-28 0001718500 rviv:VendorsMember rviv:VendorFourMember 2021-06-01 2022-02-28 0001718500 rviv:VendorsMember 2020-06-01 2021-02-28 0001718500 rviv:VendorsMember rviv:VendorOneMember 2020-06-01 2021-02-28 0001718500 rviv:VendorsMember rviv:VendorTwoMember 2020-06-01 2021-02-28 0001718500 rviv:VendorsMember rviv:VendorThreeMember 2020-06-01 2021-02-28 0001718500 rviv:VendorsMember 2021-12-01 2022-02-28 0001718500 rviv:VendorsMember rviv:VendorOneMember 2021-12-01 2022-02-28 0001718500 rviv:VendorsMember rviv:VendorTwoMember 2021-12-01 2022-02-28 0001718500 rviv:VendorsMember rviv:VendorThreeMember 2021-12-01 2022-02-28 0001718500 rviv:VendorsMember 2020-12-01 2021-02-28 0001718500 rviv:VendorsMember rviv:VendorOneMember 2020-12-01 2021-02-28 0001718500 rviv:VendorsMember rviv:VendorTwoMember 2020-12-01 2021-02-28 0001718500 us-gaap:SalesRevenueNetMember rviv:ShampoosAndConditionersMember 2021-06-01 2022-02-28 0001718500 us-gaap:SalesRevenueNetMember rviv:ShampoosAndConditionersMember 2020-06-01 2021-02-28 0001718500 us-gaap:SalesRevenueNetMember rviv:AncillaryProductsMember 2021-06-01 2022-02-28 0001718500 us-gaap:SalesRevenueNetMember rviv:AncillaryProductsMember 2020-06-01 2021-02-28 0001718500 us-gaap:SalesRevenueNetMember us-gaap:ProductMember 2021-06-01 2022-02-28 0001718500 us-gaap:SalesRevenueNetMember us-gaap:ProductMember 2020-06-01 2021-02-28 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure rviv:Customer rviv:Vendor
 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

 

FORM 10-Q

 

x    QUARTERLY REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the quarterly period ended February 28, 2022

 

o    TRANSITION REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the transition period from _____________ to _____________

 

Commission File Number: 333-220846

 

Reviv3 Procare Company

(Exact Name of Registrant as Specified in Its Charter)

 

Delaware   47-4125218
(State or Other Jurisdiction of
Incorporation or Organization)
  (I.R.S. Employer
Identification No.)
     
9480 Telstar Avenue., Unit 5, El Monte, CA   91731
(Address of Principal Executive Office)   (Zip Code)

 

(888) 638-8883

(Registrant’s Telephone Number, Including Area Code)

 

(Former name, former address and former fiscal year, if changed since last report)

 

Securities registered pursuant to Section 12(b) of the Act: None

 

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes x  No o

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer           o   Accelerated filer o
Non-accelerated Filer             o   Smaller reporting company  x
(Do not check if a smaller reporting company)   Emerging growth company x

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. x

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes o  No x

 

As of April 11, 2022, there were 41,945,881 shares of the registrant’s common stock, $0.0001 par value, outstanding.

 

 

 

 

REVIV3 PROCARE COMPANY

INDEX

 

    Page 
     
PART I - FINANCIAL INFORMATION  
     
Item 1. Financial Statements 1
     
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations 2
     
Item 3. Quantitative and Qualitative Disclosures About Market Risk 7
     
Item 4. Controls and Procedures 7
     
PART II - OTHER INFORMATION  
     
Item 1. Legal Proceedings 7
     
Item 1A. Risk Factors 8
     
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 8
     
Item 3. Defaults Upon Senior Securities 8
     
Item 4. Mine Safety Disclosures 8
     
Item 5. Other Information 8
     
Item 6. Exhibits 9
     
Signatures 10

-i-

FORWARD-LOOKING STATEMENTS

 

Except for any historical information contained herein, the matters discussed in this quarterly report on Form 10-Q contain certain “forward-looking statements’’ within the meaning of the federal securities laws. This includes statements regarding our future financial position, economic performance, results of operations, business strategy, budgets, projected costs, plans and objectives of management for future operations, and the information referred to under “Management’s Discussion and Analysis of Financial Condition and Results of Operations.”

 

These forward-looking statements generally can be identified by the use of forward-looking terminology, such as “may,’’ “will,’’ “expect,’’ “intend,’’ “estimate,’’ “anticipate,’’ “believe,’’ “continue’’ or similar terminology, although not all forward-looking statements contain these words. These forward-looking statements are not historical facts, and are based on current expectations, estimates and projections about our industry, management’s beliefs and certain assumptions made by management, many of which, by their nature, are inherently uncertain and beyond our control. Accordingly, you are cautioned that any such forward-looking statements are not guarantees of future performance and are subject to certain risks, uncertainties and assumptions that are difficult to predict. Although we believe that the expectations reflected in such forward-looking statements are reasonable as of the date made, expectations may prove to have been materially different from the results expressed or implied by such forward-looking statements. Important factors that may cause actual results to differ from projections include, for example:

 

the success or failure of management’s efforts to implement our business plan;

 

our ability to fund our operating expenses;

 

our ability to compete with other companies that have a similar business plan;

 

the effect of changing economic conditions impacting our plan of operation;

 

The scope and duration of the COVID-19 outbreak and its impact on global economic systems; and

 

our ability to meet the other risks as may be described in future filings with the Securities and Exchange Commission (the “SEC”).

 

Unless otherwise required by law, we also disclaim any obligation to update our view of any such risks or uncertainties or to announce publicly the result of any revisions to the forward-looking statements made in this quarterly report on Form 10-Q.

 

When considering these forward-looking statements, you should keep in mind the cautionary statements in this quarterly report on Form 10-Q and in our other filings with the SEC. We cannot assure you that the forward-looking statements in this quarterly report on Form 10-Q will prove to be accurate. Furthermore, if our forward-looking statements prove to be inaccurate, the inaccuracy may prove to be material. In light of the significant uncertainties in these forward-looking statements, you should not regard these statements as a representation or warranty by us or any other person that we will achieve our objectives and plans in any specified timeframe, or at all.

-ii-

PART 1 – FINANCIAL INFORMATION

 

ITEM 1. FINANCIAL STATEMENTS

 

REVIV3 PROCARE COMPANY

INDEX TO FINANCIAL STATEMENTS

FEBRUARY 28, 2022

 

CONTENTS

 

Financial Statements:  
   
Balance Sheets - As of February 28, 2022 (Unaudited) and May 31, 2021 F-1
   
Statements of Operations - For the three and nine months ended February 28, 2022 and 2021 (Unaudited) F-2
   
Statements of Changes in Stockholders’ Equity - For the three and nine months ended February 28, 2022 and 2021 (Unaudited) F-3
   
Statements of Cash Flows – For the nine months ended February 28, 2022 and 2021 (Unaudited) F-4
   
Condensed Notes to Unaudited Financial Statements F-5

-1-

REVIV3 PROCARE COMPANY
 BALANCE SHEETS

 

   February 28   May 31, 
   2022   2021 
   (Unaudited)     
ASSETS          
CURRENT ASSETS:          
Cash  $445,945   $496,937 
Accounts receivable, net   68,813    90,877 
Inventory, net   317,012    450,978 
Prepaid expenses and other current assets   37,463    2,430 
           
Total Current Assets   869,233    1,041,222 
           
OTHER ASSETS:          
Inventory, non-current   39,130    39,874 
Property and equipment, net   30,413    37,016 
Deposits   16,277    16,277 
Right of use assets, net   67,144    128,375 
           
Total Other Assets   152,964    221,542 
           
TOTAL ASSETS  $1,022,197   $1,262,764 
           
LIABILITIES AND STOCKHOLDERS’ EQUITY          
           
CURRENT LIABILITIES:          
Accounts payable and accrued expenses  $434,660   $458,962 
Customer deposits   35,043    106,949 
Due to related party   61,659    54,304 
Equipment payable, current   3,300    3,300 
Loan payable, current   156,300    4,261 
Lease liability, current   69,714    84,635 
           
Total Current Liabilities   760,676    712,411 
           
LONG TERM LIABILITIES:          
Equipment payable   3,025    5,500 
Loan payable       152,039 
Lease liability, non- current       47,166 
           
Total Long Term Liabilities   3,025    204,705 
           
Total Liabilities   763,701    917,116 
           
Commitments and contingencies (see Note 10)        
           
STOCKHOLDERS’ EQUITY:          
Preferred stock, $0.0001 par value; 20,000,000 shares authorized; none issued and outstanding        
Common stock, $0.0001 par value: 100,000,000 shares authorized; 41,945,881 shares issued, issuable and outstanding as of February 28, 2022 and May 31, 2021, respectively   4,195    4,195 
Additional paid-in capital   5,450,117    5,450,117 
Accumulated deficit   (5,195,816)   (5,108,664)
           
Total Stockholders’ Equity   258,496    345,648 
           
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY  $1,022,197   $1,262,764 

 

See accompanying notes to these unaudited financial statements.

F-1

REVIV3 PROCARE COMPANY
 STATEMENTS OF OPERATIONS
 (UNAUDITED)

 

                             
   For the Three Months Ended   For the Nine Months Ended 
   February 28,   February 28,   February 28,   February 28, 
   2022   2021   2022   2021 
Sales  $476,384   $364,966   $1,809,472   $1,277,480 
                     
Cost of sales   134,609    93,491    611,305    477,578 
                     
Gross profit   341,775    271,475    1,198,167    799,902 
                     
OPERATING EXPENSES:                    
Marketing and selling expenses   317,981    201,247    938,654    501,051 
Compensation and related taxes   3,521    9,065    15,129    26,868 
Professional and consulting expenses   56,846    108,132    176,400    197,611 
General and administrative   60,928    74,059    185,196    208,881 
                     
Total Operating Expenses   439,276    392,503    1,315,379    934,411 
                     
LOSS FROM OPERATIONS   (97,501)   (121,028)   (117,212)   (134,509)
                     
OTHER INCOME (EXPENSE):                    
Gain on debt settlement       16,313    35,000    16,313 
Interest income   10    12    28    31 
Interest expense and other finance charges   (1,823)   (1,757)   (4,968)   (4,461)
                     
Other Income (Expense), Net   (1,813)   14,568    30,060    11,883 
                     
LOSS BEFORE PROVISION FOR INCOME TAXES   (99,314)   (106,460)   (87,152)   (122,626)
                     
Provision for income taxes                
                     
NET LOSS  $(99,314)  $(106,460)  $(87,152)  $(122,626)
                     
NET LOSS PER COMMON SHARE - Basic and diluted  $(0.00)  $(0.00)  $(0.00)  $(0.00)
                     
WEIGHTED AVERAGE COMMON SHARES OUTSTANDING:                    
Basic and diluted   41,945,881    41,817,566    41,945,881    41,479,141 

 

See accompanying notes to these unaudited financial statements.

F-2

REVIV3 PROCARE COMPANY
STATEMENTS OF CHANGES IN STOCKHOLDERS’ EQUITY
FOR THE THREE AND NINE MONTHS ENDED FEBRUARY 28, 2022 AND 2021
(UNAUDITED)

 

                                                         
For the nine months ended February 28, 2022
                             
       Common Stock           Total 
   Preferred Stock   Issued And Issuable   Additional Paid-in   Accumulated   Stockholders’ 
   Shares   Amount   Shares   Amount   Capital   Deficit   Equity 
Balance, May 31, 2021      $    41,945,881   $4,195   $5,450,117   $(5,108,664)  $345,648 
                                    
Net loss for the nine months ended February 28, 2022                       (87,152)   (87,152)
                                    
Balance, February 28, 2022      $    41,945,881   $4,195   $5,450,117   $(5,195,816)  $258,496 
 
For the three months ended February 28, 2022
                             
       Common Stock           Total 
   Preferred Stock   Issued And Issuable   Additional Paid-in   Accumulated   Stockholders’ 
   Shares   Amount   Shares   Amount   Capital   Deficit   Equity 
Balance, November 30, 2021      $    41,945,881   $4,195   $5,450,117   $(5,096,502)  $357,810 
                                    
Net loss for the three months ended February 28, 2022                       (99,314)   (99,314)
                                    
Balance, February 28, 2022      $    41,945,881   $4,195   $5,450,117   $(5,195,816)  $258,496 
 
For the nine months ended February 28, 2021
                             
       Common Stock           Total 
   Preferred Stock   Issued And Issuable   Additional Paid-in   Accumulated   Stockholders’ 
   Shares   Amount   Shares   Amount   Capital   Deficit   Equity 
Balance, May 31, 2020      $    41,285,881   $4,129   $5,311,383   $(4,810,909)  $504,603 
                                    
Shares issued for services           440,000    44    66,356        66,400 
                                    
Shares to be issued for services                   25,200        25,200 
                                    
Net loss for the nine months ended February 28, 2021                       (122,626)   (122,626)
                                    
Balance, February 28, 2021      $    41,725,881   $4,173   $5,402,939   $(4,933,535)  $473,577 
 
For the three months ended February 28, 2021
                             
       Common Stock           Total 
   Preferred Stock   Issued And Issuable   Additional Paid-in   Accumulated   Stockholders’ 
   Shares   Amount   Shares   Amount   Capital   Deficit   Equity 
Balance, November 30, 2020      $    41,485,881   $4,149   $5,327,363   $(4,827,075)  $504,437 
                                    
Shares issued for services           240,000    24    50,376        50,400 
                                    
Shares to be issued for services                   25,200        25,200 
                                    
Net loss for the three months ended February 28, 2021                       (106,460)   (106,460)
                                    
Balance, February 28, 2021      $    41,725,881   $4,173   $5,402,939   $(4,933,535)  $473,577 

 

See accompanying notes to these unaudited financial statements.

F-3

REVIV3 PROCARE COMPANY
STATEMENTS OF CASH FLOWS
(UNAUDITED)

 

   For the Nine Months Ended 
   February 28,   February 28, 
   2022   2021 
CASH FLOWS FROM OPERATING ACTIVITIES          
Net loss  $(87,152)  $(122,626)
Adjustments to reconcile net loss to net cash provided by (used in) operating activities:          
Depreciation   6,603    7,622 
Bad debts   3,012    574 
Stock based compensation       66,400 
Gain on debt settlement   (35,000)   (16,313)
Non cash lease expense       1,714 
Change in operating assets and liabilities:          
Accounts receivable   19,052    89,683 
Inventory   134,710    (13,399)
Prepaid expenses and other current assets   (35,033)   (64,513)
Accounts payable and accrued expenses   (24,303)   236,094 
Lease liability   (857)    
Customer deposits   (71,905)   (111,024)
           
NET CASH PROVIDED BY (USED IN) OPERATING ACTIVITIES   (90,873)   74,212 
           
CASH FLOWS FROM INVESTING ACTIVITIES          
Purchase of property and equipment       (15,408)
           
NET CASH USED IN INVESTING ACTIVITIES       (15,408)
           
CASH FLOWS FROM FINANCING ACTIVITIES          
Proceeds from loan payable   35,000    6,300 
Repayment of equipment financing   (2,475)   (2,475)
Advances from a related party, net   7,356    20,406 
           
NET CASH PROVIDED BY FINANCING ACTIVITIES   39,881    24,231 
           
NET INCREASE/(DECREASE) IN CASH   (50,992)   83,035 
           
CASH - Beginning of period   496,937    409,031 
           
CASH - End of period  $445,945   $492,066 
           
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:          
Cash paid during the period for:          
Interest  $375   $375 
Income taxes  $   $ 

 

See accompanying notes to these unaudited financial statements.

F-4

REVIV3 PROCARE COMPANY 

CONDENSED NOTES TO UNAUDITED FINANCIAL STATEMENTS 

FEBRUARY 28, 2022

 

Note 1 – Organization

 

Reviv3 Procare Company (the “Company”) was incorporated in the State of Delaware on May 21, 2015, as a reorganization of Reviv3 Procare, LLC which was organized on July 31, 2013. The Company is engaged in the manufacturing, marketing, sale and distribution of professional quality hair and skin care products throughout the United States, Canada, Europe and Asia.

 

Note 2 – Basis of Presentation and Summary of Significant Accounting Policies

 

Basis of Presentation

 

The unaudited financial statements for the three and nine months ended February 28, 2022, and 2021 have been prepared by us pursuant to the rules and regulations of the Securities and Exchange Commission. In the opinion of the management, all adjustments necessary to present fairly our financial position, results of operations, and cash flows as of February 28, 2022, and 2021, and for the periods then ended, have been made. Those adjustments consist of normal and recurring adjustments. Certain information and note disclosures normally included in our annual financial statements prepared in accordance with generally accepted accounting principles have been omitted. The unaudited financial statements should be read in conjunction with the financial statements and notes thereto included in the Company’s annual report on Form 10-K for the year ended May 31, 2021. The results of operations for the three and nine months ended February 28, 2022 are not necessarily indicative of the results to be expected for the full year.

 

Risk and Uncertainty Concerning COVID-19 Pandemic

 

In March 2020, the World Health Organization declared the outbreak of a novel coronavirus (COVID-19) as a pandemic which continues to spread throughout the United States and the World. We are currently monitoring the outbreak of COVID-19 and the related business and travel restrictions and changes to behavior intended to reduce its spread. All of our Chinese facilities were temporarily closed for a period of time. Most of these facilities have been reopened since July 2020. Depending on the progression of the outbreak, our ability to obtain necessary supplies and ship finished products to customers may be partly or completely disrupted globally. Also, our ability to maintain appropriate labor levels could be disrupted. If the coronavirus continues to progress, it could have a material negative impact on our results of operations and cash flow, in addition to the impact on its employees. We have concluded that while it is reasonably possible that the virus could have a negative impact on the results of operations, the specific impact is not readily determinable as of the date of these financial statements. The accompanying financial statements do not include any adjustments that might result from the outcome of this uncertainty. Management is focused on growing the Company’s existing products offering, as well as its customer base, to increase its revenues. The Company cannot give assurance that it can increase its cash balances or limit its cash consumption and thus maintain sufficient cash balances for its planned operations or future acquisitions. Future business demands may lead to cash utilization at levels greater than recently experienced. The Company may need to raise additional capital in the future. However, the Company cannot assure that it will be able to raise additional capital on acceptable terms, or at all. Subject to the foregoing, management believes that the Company has sufficient capital and liquidity to fund its operations for at least one year from the date of issuance of the accompanying financial statements.

 

Going Concern

 

As reflected in the accompanying financial statements, the Company had an accumulated deficit of $5,195,816 at February 28, 2022. Additionally, the Company incurred a net loss of $87,152 and net cash used in operations of $90,873 for the nine months ended February 28, 2022. This raises substantial doubt about the Company’s ability to continue as a going concern for a period of 12 months from the issuance date of this report. The ability of the Company to continue as a going concern is dependent on the Company’s ability to implement its business plan, raise capital, and generate sufficient revenue; however, the Company’s cash position may not be sufficient to support its daily operations. Management intends to raise additional funds by way of a private or public offering. While the Company believes in the viability of its strategy to further implement its business plan and generate sufficient revenue and in its ability to raise additional funds, there can be no assurances to that effect. The financial statements do not include any adjustments related to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.

F-5

REVIV3 PROCARE COMPANY 

CONDENSED NOTES TO UNAUDITED FINANCIAL STATEMENTS 

FEBRUARY 28, 2022

 

Note 2 – Basis of Presentation and Summary of Significant Accounting Policies (continued)

 

Use of estimates

 

The preparation of the financial statements in conformity with accounting principles generally accepted in the U.S. requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues, expenses, and the related disclosures at the date of the financial statements and during the reporting period. Actual results could materially differ from these estimates. Significant estimates made by management include, but are not limited to, the allowance for doubtful accounts, inventory valuations and classifications, the useful life of property and equipment, the valuation of deferred tax assets, the value of stock-based compensation, valuation of lease liabilities and related right of use assets and the fair value of non-cash common stock issuances. 

 

Cash and cash equivalents

 

The Company considers all highly liquid debt instruments and other short-term investments with maturities of three months or less, when purchased, to be cash equivalents.  The Company maintains cash and cash equivalent balances at one financial institution that is insured by the Federal Deposit Insurance Corporation.

 

Accounts receivable and allowance for doubtful accounts

 

The Company has a policy of providing on allowance for doubtful accounts based on its best estimate of the amount of probable credit losses in its existing accounts receivable.  The Company periodically reviews its accounts receivable to determine whether an allowance is necessary based on an analysis of past due accounts and other factors that may indicate that the realization of an account may be in doubt.  Account balances deemed to be uncollectible are charged to bad debt expense and included in the allowance after all means of collection have been exhausted and the potential for recovery is considered remote.

 

Prepaid expenses and other current assets

 

Prepaid expenses and other current assets of $37,463 and $2,430 at February 28, 2022, and May 31, 2021, respectively, consist primarily of cash prepayments to vendors which will be utilized within a year.   

 

Inventory

 

The Company values inventory, consisting of finished goods and raw materials, at the lower of cost and net realizable value. Cost is determined using an average cost method. The Company reduces inventory for the diminution of value, resulting from product obsolescence, damage or other issues affecting marketability, equal to the difference between the cost of the inventory and its net realizable value. The Company evaluates its current level of inventory considering historical sales and other factors and, based on this evaluation, classifies inventory markdowns in the statement of operations as a component of cost of goods sold. These markdowns are estimates, which could vary significantly from actual requirements if future economic conditions, customer demand or competition differ from expectations.  

 

Property and Equipment

 

Property and equipment are carried at cost less accumulated depreciation.  Depreciation is computed using the straight-line method over the estimated useful lives of the assets. The cost of repairs and maintenance is expensed as incurred; major replacements and improvements are capitalized.  When assets are retired or disposed of, the cost and accumulated depreciation are removed, and any resulting gains or losses are included in the statement of operations. 

F-6

REVIV3 PROCARE COMPANY 

CONDENSED NOTES TO UNAUDITED FINANCIAL STATEMENTS 

FEBRUARY 28, 2022

 

Note 2 – Basis of Presentation and Summary of Significant Accounting Policies (continued)

 

Revenue recognition

 

The Company follows Accounting Standards Codification (“ASC”) 606, Revenue From Contracts With Customers. This revenue recognition standard has a five steps process: a) Determine whether a contract exists; b) Identify the performance obligations; c) Determine the transaction price; d) Allocate the transaction price; and e) Recognize revenue when (or as) performance obligations are satisfied.

 

The Company sells a variety of hair and skin care products. The Company recognizes revenue for the agreed upon sales price when a purchase order is received from the customer and subsequently the product is shipped to the customer, which satisfies the performance obligation. Consideration paid to the customer to promote and sell the Company’s products is typically recorded as a reduction in revenues. See Note 12 for revenue disaggregation disclosures.

 

Cost of Sales

 

The primary components of cost of sales include the cost of the product and shipping fees.

 

Shipping and Handling Costs

 

The Company accounts for shipping and handling fees in accordance with ASC 606. While amounts charged to customers for shipping products are included in revenues, the related costs of shipping products to customers are classified in marketing and selling expenses as incurred. Shipping costs included in marketing and selling expense were $47,894 and $36,853 for the three months ended February 28, 2022 and 2021, respectively. Shipping costs included in marketing and selling expense were $170,466 and $90,669 for the nine months ended February 28, 2022 and 2021, respectively.

 

Marketing, selling and advertising

 

Marketing, selling and advertising costs are expensed as incurred.

 

Customer Deposits

 

Customer deposits consisted of prepayments from customers to the Company. The Company will recognize the prepayments as revenue upon delivery of products in compliance with its revenue recognition policy.

 

Fair value measurements and fair value of financial instruments

 

The Company adopted Accounting Standards Codification (“ASC”) 820, “Fair Value Measurements and Disclosures” (“ASC 820”), for assets and liabilities measured at fair value on a recurring basis. ASC 820 establishes a common definition for fair value to be applied to existing generally accepted accounting principles that requires the use of fair value measurements, establishes a framework for measuring fair value and expands disclosure about such fair value measurements. The adoption of ASC 820 did not have an impact on the Company’s financial position or operating results, but did expand certain disclosures. ASC 820 defines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date.

 

Additionally, ASC 820 requires the use of valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs. These inputs are prioritized below: 

 

Level 1:   Observable inputs such as quoted market prices in active markets for identical assets or liabilities
   
Level 2:   Observable market-based inputs or unobservable inputs that are corroborated by market data
   
Level 3:   Unobservable inputs for which there is little or no market data, which require the use of the reporting entity’s own assumptions.

F-7

REVIV3 PROCARE COMPANY 

CONDENSED NOTES TO UNAUDITED FINANCIAL STATEMENTS 

FEBRUARY 28, 2022

 

Note 2 – Basis of Presentation and Summary of Significant Accounting Policies (continued)

 

The Company analyzes all financial instruments with features of both liabilities and equity under the Financial Accounting Standard Board’s (“FASB”) accounting standard for such instruments. Under this standard, financial assets and liabilities are classified in their entirety based on the lowest level of input that is significant to the fair value measurement.

 

The estimated fair value of certain financial instruments, including prepaid expenses, deposits, accounts payable and accrued expenses are carried at historical cost basis, which approximates their fair values because of the short-term nature of these instruments. 

 

Impairment of long-lived assets  

 

The Company reviews long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of the assets may not be fully recoverable, or at least annually. The Company recognizes an impairment loss when the sum of expected undiscounted future cash flows is less than the carrying amount of the asset. The amount of impairment is measured as the difference between the asset’s estimated fair value and its book value. The Company did not record any impairment loss during the nine months ended February 28, 2022 and 2021.

 

Stock-based compensation

 

Stock-based compensation is accounted for based on the requirements of the Share-Based Payment Topic of ASC 718, “Compensation — Stock Compensation” (“ASC 718”), which requires recognition in the financial statements of the cost of employee and non-employee services received in exchange for an award of equity instruments over the period the employee or non-employee is required to perform the services in exchange for the award (presumptively, the vesting period). ASC 718 also requires measurement of the cost of employee, non-employee and director services received in exchange for an award based on the grant-date fair value of the award.

 

Net loss per share of common stock

 

Basic net loss per share is computed by dividing the net loss by the weighted average number of common shares during the period. Diluted net loss per share is computed using the weighted average number of common shares and potentially dilutive securities outstanding during the period. At February 28, 2022 and 2021, the Company had no potentially dilutive securities outstanding related to common stock.

 

Lease Accounting

 

In February 2016, the FASB issued ASU No. 2016-02, Leases (“ASU 2016-02), which requires lessees to report on their balance sheets a right-of-use asset and a lease liability in connection with most lease agreements classified as operating leases under the prior guidance (ASC Topic 840). Under the new guidance, codified as ASC Topic 842, the lease liability must be measured initially based on the present value of future lease payments, subject to certain conditions. The right-of-use asset must be measured initially based on the amount of the liability, plus certain initial direct costs. The new guidance further requires that leases be classified at inception as either (a) operating leases or (b) finance leases. For operating leases, periodic expense generally is flat (straight-line) throughout the life of the lease. For finance leases, periodic expense declines over the life of the lease. The new standard, as amended, provides an option for entities to use the cumulative-effect transition method. As permitted, the Company adopted ASC Topic 842 effective June 1, 2019. The adoption of ASC Topic 842 did not have a material impact on the Company’s financial statements.

 

The Company renewed lease for its corporate headquarters commencing December 1, 2019, under lease agreements classified as an operating lease. Please see Note 10 – “Leases” below for more information about the Company’s leases. 

F-8

REVIV3 PROCARE COMPANY 

CONDENSED NOTES TO UNAUDITED FINANCIAL STATEMENTS 

FEBRUARY 28, 2022

 

Note 2 – Basis of Presentation and Summary of Significant Accounting Policies (continued)

 

Recently Issued Accounting Pronouncements

 

In August 2020, the FASB issued ASU No. 2020-06, Debt – Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging – Contracts in Entity’s Own Equity (ASU 2020-06), which simplifies the accounting for certain convertible instruments. Among other things, under ASU 2020-06, the embedded conversion features no longer must be separated from the host contract for convertible instruments with conversion features not required to be accounted for as derivatives, or that do not result in substantial premiums accounted for as paid-in capital. ASU 2020-06 also eliminates the use of the treasury stock method when calculating the impact of convertible instruments on diluted Earnings per Share. For the Company, the provisions of ASU 2020-06 are effective for its fiscal year beginning on June 1, 2024. Early adoption is permitted, subject to certain limitations. The Company is evaluating the potential impact of adoption on its financial statements.

 

In December 2019, the FASB issued ASU No. 2019-12, Income Taxes (Topic 740) – Simplifying the Accounting for Income Taxes (“ASU 2019-12”). ASU 2019-12, among other things, (a) eliminates the exception to the incremental approach for intra-period tax allocation when there is a loss from continuing operations and income (or a gain) from other items, (b) eliminates the exception to the general methodology for calculating income taxes in an interim period when the year-to-date loss exceeds the anticipated loss for the year, (c) requires than an entity recognize a franchise tax (or a similar tax) that is partially based on income as an income-based tax and account for any incremental amount incurred as a non-income-based tax, and (d) requires than an entity reflect the effect of an enacted change in tax laws or rates in the annual effective tax rate computation for the interim period that includes the enactment date. For public companies, these amendments are effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2020. The Company adopted ASU 2019-12 effective June 1, 2021 and based on its preliminary evaluation it does not believe adoption had a material impact on its unaudited financial statements.

 

Other accounting standards that have been issued or proposed by FASB that do not require adoption until a future date are not expected to have a material impact on the financial statements upon adoption. The Company does not discuss recent pronouncements that are not anticipated to have an impact on or are unrelated to its financial condition, results of operations, cash flows or disclosures.

 

Note 3 – Accounts Receivable, net

 

Accounts receivable, consisted of the following:

 

   February 28, 2022   May 31, 2021 
Accounts Receivable  $74,704   $93,756 
Less: Allowance for doubtful debts   (5,891)   (2,879)
Accounts receivable, net  $68,813   $90,877 

   

The Company recorded bad debt expense of $3,012 and $574 during the nine months ended February 28, 2022 and 2021, respectively. The Company recorded bad debt expense of $696 and $0 during the three months ended February 28, 2022 and 2021, respectively. 

F-9

REVIV3 PROCARE COMPANY 

CONDENSED NOTES TO UNAUDITED FINANCIAL STATEMENTS 

FEBRUARY 28, 2022

 

Note 4 – Inventory

 

Inventory consisted of the following:

 

At February 28, 2022 and May 31, 2021, inventory held at third party locations amounted to $17,179 and $23,401, respectively. At February 28, 2022 and May 31, 2021, there was no inventory in- transit.

 

 

   February 28, 2022   May 31, 2021 
Finished Goods  $9,735   $15,056 
Raw Materials  $346,407   $475,796 
Inventory, Net  $356,142   $490,852 
Less: Inventory, non-current  $(39,130)  $(39,874)
Current Inventory  $317,012   $450,978 

 

As of February 28, 2022 and May 31, 2021, the Company had an allowance of $19,156 on slow moving inventory. The Company also reclassed some slow-moving inventory, comprising of bottles and packaging, amounting to $39,130 and $39,874, as non-current inventory, as of February 28, 2022 and May 31, 2021, respectively.

 

Note 5 – Property and Equipment

 

Property and equipment, stated at cost, consisted of the following:

 

   Estimated Life  February 28, 2022   May 31, 2021 
Furniture and Fixtures  5 years  $5,759   $5,759 
Computer Equipment  3 years   17,392    17,392 
Plant Equipment  5-10 years   45,128    45,128 
Less: Accumulated Depreciation      (37,866)   (31,263)
Property and equipment, net     $30,413   $37,016 

 

Depreciation expense amounted to $2,128 and $2,712 for the three months ended February 28, 2022 and 2021, respectively. Depreciation expense amounted to $6,603 and $7,622 for the nine months ended February 28, 2022 and 2021, respectively. 

 

Note 6 – Accounts Payable and Accrued Expenses

 

Accounts payable and accrued expenses comprised of the following:

 

   February 28, 2022   May 31, 2021 
Trade Payables  $410,560   $436,138 
Credit Cards   7,622    11,115 
Accrued Interest and Other   16,478    11,709 
Accounts Payable and Accrued Expenses, net  $434,660   $458,962 

 

Note 7 – Equipment Payable

 

During the year ended May 31, 2019, the Company purchased a forklift under an installment purchase plan. The loan amount is $16,500 payable in 60 monthly instalment payments of $317 comprising of principal payment of $275 and interest payment of $42. As at February 28, 2022 and May 31, 2021, the balance outstanding on the loan was $6,325 and $8,800, respectively, of which $3,300 is payable within one year and the balance is payable after one year. The Company recorded an interest expense of $125 and $125, during the three months ended February 28, 2022 and 2021, on the loan in the accompanying financial statements. The Company recorded an interest expense of $375 and $375, during the nine months ended February 28, 2022 and 2021, on the loan in the accompanying financial statements.

F-10

REVIV3 PROCARE COMPANY 

CONDENSED NOTES TO UNAUDITED FINANCIAL STATEMENTS 

FEBRUARY 28, 2022

 

The amounts of loan payments due in the next two years ended February 28, are as follows:

 

   Total 
     
2022  $3,300 
2023  $3,025 
      
Equipment Payable, Net  $6,325 

 

Note 8 – Loan Payable

 

During the year ended May 31, 2020, a commercial bank granted to the Company a loan (the “Loan”) in the amount of $12,900, which is administered under the authority and regulations of the U.S. Small Business Administration pursuant to the Paycheck Protection Program (the “PPP”) of the Coronavirus Aid, Relief, and Economic Security Act (the “CARES Act”). The Loan was evidenced by a note dated May 8, 2020, bore interest at an annual rate of 1.0% and matured on May 8, 2022. The Note may be prepaid without penalty, at the option of the Company, at any time prior to maturity. Proceeds from loans granted under the CARES Act are intended to be used for payroll, costs to continue employee group health care benefits, rent, utilities, and certain other qualified costs (collectively, “qualifying expenses”). The Company intends to use the loan proceeds for qualifying expenses. The Company’s borrowings under the Loan may be eligible for loan forgiveness if used for qualifying expenses incurred during the “covered period,” as defined in the CARES Act, except that the amount of loan forgiveness is limited to the amount of qualifying expenses incurred during the 8-week period commencing on the loan effective date. In addition, the amount of any loan forgiveness may be reduced if there is a decrease in the average number of full-time equivalent employees of the Company during the covered period, compared to the comparable period in the prior calendar year. The Company’s indebtedness, after any such loan forgiveness, is payable in 18 equal monthly installments commencing on November 8, 2020, with all amounts due and payable by the maturity. The Company did not pay any instalment of the loan and recorded an accrued interest of $120 on the loan during the year ended May 31, 2021. On March 19, 2021 the loan was forgiven by the US Small Business Administration and the Company recorded a gain on debt forgiveness of $13,020.

 

During the year ended May 31, 2020, a commercial bank granted to the Company a loan (the “Loan”) in the amount of $150,000, which is administered under the authority and regulations of the U.S. Small Business Administration pursuant to the Economic Injury Disaster Loan Program (the “EIDL”) of the Coronavirus Aid, Relief, and Economic Security Act (the “CARES Act”). The Loan, which is evidenced by a note dated May 18, 2020, bears interest at an annual rate of 3.75% and is payable installments of $731 per month, beginning May 18, 2021 until May 13, 2050. The Company has to maintain a hazard insurance policy including fire, lightning, and extended coverage on all items used to secure this loan to at least 80% of the insurable value. Proceeds from loans granted under the CARES Act are intended to be used for payroll, costs to continue employee group health care benefits, rent, utilities, and certain other qualified costs (collectively, “qualifying expenses”). The Company intends to use the loan proceeds for qualifying expenses. The Company’s borrowings under the loan are eligible for up to $10,000 of loan forgiveness. The Company received a loan forgiveness for $10,000 during the nine months ended February 28, 2022. During the nine months ended February 28, 2022, the Company received additional $10,000 of borrowings under the program. The Company recorded an accrued interest of $10,254 and $5,923, as of February 28, 2022 and May 31, 2021, respectively. The Company has not paid any instalment of the loan as of February 28, 2022 and the loan is currently in default.

 

On February 7, 2021, a commercial bank granted to the Company a loan (the “Loan”) in the amount of $6,300, which is administered under the authority and regulations of the U.S. Small Business Administration pursuant to the Second Draw Paycheck Protection Program (the “PPP”) of the Coronavirus Aid, Relief, and Economic Security Act (the “CARES Act”). The Loan, which is evidenced by a note dated February 7, 2021, bears interest at an annual rate of 1.0% and matures on February 6, 2026. The Note may be prepaid without penalty, at the option of the Company, at any time prior to maturity. Proceeds from loans granted under the CARES Act are intended to be used for payroll, costs to continue employee group health care benefits, rent, utilities, and certain other qualified costs (collectively, “qualifying expenses”). The Company intends to use the loan proceeds for qualifying expenses. The Company’s borrowings under the Loan may be eligible for loan forgiveness if used for qualifying expenses incurred during the “covered period,” as defined in the CARES Act. The Company’s indebtedness, after any such loan forgiveness, is payable in 54 equal monthly installments commencing on September 7, 2021, with all amounts due and payable by the maturity. The Company recorded an accrued interest of $62 and $0, as of February 28, 2022 and May 31, 2021, respectively. The Company has not paid any instalment of the loan as of February 28, 2022 and the loan is currently in default. 

F-11

REVIV3 PROCARE COMPANY 

CONDENSED NOTES TO UNAUDITED FINANCIAL STATEMENTS 

FEBRUARY 28, 2022

 

During the nine-month period ended February 28, 2022, the Company received $25,000 in grant awards pursuant to the California Small Business Covid-19 Relief Grant Program. This grant was recorded as other income in the accompanying unaudited financial statements as no repayment is required to be made.

 

   February 28, 2022   May 31, 2021 
Second Draw Paycheck Protection Program (PPP- 2)  $6,300   $6,300 
Economic Injury Disaster Loan Program (EIDL)  $150,000   $150,000 
Total  $156,300   $156,300 
Less: Current portion  $156,300   $4,261 
Non-current portion  $   $152,039 

 

The amounts of loan payments due in the upcoming years ended February 28, are as follows:

 

   Total 
2022  $7,638 
2023  $4,618 
2024  $4,755 
2025  $4,897 
2026  $3,597 
Thereafter  $130,795 
Total  $156,300 

 

Note 9 – Stockholders’ Equity

 

Shares Authorized

 

The authorized capital of the Company consists of 100,000,000 shares of common stock, par value $0.0001 per share and 20,000,000 shares of preferred stock, par value $0.0001 per share.

 

Preferred Stock

 

The preferred stock may be issued from time to time in one or more series. The Board of Directors of the Company is expressly authorized to provide for the issuance of all or any of the shares of the preferred stock in one or more series, and to fix the number of shares and to determine or alter, for each such series, such voting powers, full or limited, or no voting powers and such designations, preferences, and relative, participating, optional, or other rights and such qualifications, limitations, or restrictions thereof, as shall be stated and expressed until the resolution adopted by the Board of Directors providing the issuance of such shares. The Board of Directors is also expressly authorized to increase or decrease the number of shares of any series subsequent to the issue of shares of that series. In case the number of shares of any such series shall be so decreased, the decrease shall resume the status that they had prior to the adoption of the resolution originally fixing the number of shares of such series. 

F-12

REVIV3 PROCARE COMPANY

CONDENSED NOTES TO UNAUDITED FINANCIAL STATEMENTS

FEBRUARY 28, 2022

 

Common Stock

 

As of February 28, 2022, 41,945,881 shares of common stock were issued and outstanding.

 

No shares were issued during the nine months period ended February 28, 2022.

 

During the nine months period ended February 28, 2021, the Company issued 200,000 shares to a consultant for past services. The shares were valued at the fair market value of the $16,000, which expense was recognized immediately.

 

During the nine months ended February 28, 2021, the Company issued 240,000 shares to a consultant for services. The shares were valued at the fair market value of the $50,400, which expense was recognized over the term of the services. The Company recognized $25,200 as expense during the nine months ended February 28, 2021 and the balance $25,200 was recognized as a prepayment.

 

During the nine months ended February 28, 2021, the Company recorded $25,200 for 60,000 shares to be issued to an attorney for past services. The shares were valued at the fair market value, which expense was recognized immediately. The shares were issued in March 2021.

 

Note 10 – Commitments and contingencies

 

Leases

 

As discussed in Note 2 above, the Company adopted ASU No. 2016-02, Leases on June 1, 2019, which require lessees to report on their balance sheets a right-of-use asset and a lease liability in connection with most lease agreements classified as operating leases under the prior guidance. The Company has a lease agreement in connection with its office and warehouse facility in California under an operating lease which expired in October 2019. On December 1, 2019, the Company signed an extension of the lease for 3 years. The rent will be $7,567 per month for the first year and increase by a certain amount each year.

 

The Company treats a contract as a lease when the contract conveys the right to use a physically distinct asset for a period of time in exchange for consideration, or the Company directs the use of the asset and obtains substantially all the economic benefits of the asset. These leases are recorded as right-of-use (“ROU”) assets and lease obligation liabilities for leases with terms greater than 12 months. ROU assets represent the Company’s right to use an underlying asset for the entirety of the lease term. Lease liabilities represent the Company’s obligation to make payments over the life of the lease. A ROU asset and a lease liability are recognized at commencement of the lease based on the present value of the lease payments over the life of the lease. Initial direct costs are included as part of the ROU asset upon commencement of the lease. Since the interest rate implicit in a lease is generally not readily determinable for the operating leases, the Company uses an incremental borrowing rate to determine the present value of the lease payments. The incremental borrowing rate represents the rate of interest the Company would have to pay to borrow on a collateralized basis over a similar lease term to obtain an asset of similar value.

 

The Company reviews the impairment of ROU assets consistent with the approach applied for the Company’s other long-lived assets. The Company reviews the recoverability of long-lived assets when events or changes in circumstances occur that indicate that the carrying value of the asset may not be recoverable. The assessment of possible impairment is based on the Company’s ability to recover the carrying value of the asset from the expected undiscounted future pre-tax cash flows of the related operations.

 

Lease expense is recognized on a straight-line basis over the lease term, while variable lease payments are expensed as incurred. Variable payments change due to facts or circumstances occurring after the commencement date, other than the passage of time, and do not result in a remeasurement of lease liabilities. The Company’s lease agreements do not contain any residual value guarantees or restrictive covenants.

 

Pursuant to the new standard, the Company recorded an initial lease liability of $235,748 and an initial right of use asset in the same amount. During the three months ended February 28, 2022 and 2021, the Company recorded a lease expense in the amount of $23,559 and $23,559, respectively. During the nine months ended February 28, 2022 and 2021, the Company recorded a lease expense in the amount of $70,676 and $70,676, respectively. As of February 28, 2022, the lease liability balance was $69,714 and the right of use asset balance was $67,144. A lease term of three years and a discount rate of 12% was used.

F-13

REVIV3 PROCARE COMPANY

CONDENSED NOTES TO UNAUDITED FINANCIAL STATEMENTS

FEBRUARY 28, 2022

 

Supplemental balance sheet information related to leases was as follows:

 

Assets  February 28, 2022 
Right of use assets  $235,748 
Accumulated reduction   (168,604)
Operating lease assets, net  $67,144 
      
Liabilities     
Lease liability  $235,748 
Accumulated reduction   (166,034)
Total lease liability, net   69,714 
Current portion   (69,714)
Non-current portion  $ 

 

Maturities of operating lease liabilities were as follows as of February 28, 2022:

 

Operating Lease    
Year 1  $73,246 
Total  $73,246 
Less: Imputed interest  $(3,532)
Present value of lease liabilities  $69,714 

 

Contingencies

 

On November 23, 2020, the Company was served a copy of a complaint filed by Jacksonfill, LLC in the Fourth Circuit Court for Duval County, Florida. The complaint alleges breach of Agreement for non-payments for certain products against the Company. The allegations arise from alleged discrepancies discovered by the Company in the manufacturing of certain product. The Company has retained counsel and intends to vigorously defend the allegations. The product was delivered to the Company. However, the Company believes that the product was defective. The amount of the claim of $204,182 has been recorded as accounts payable, in the accompanying financial statements as of February 28, 2022.

 

Note 11 – Related Party Transactions

 

The Company’s Chief Executive Officer, from time to time, provided advances to the Company for working capital purposes. At February 28, 2022 and May 31, 2021, the Company had a payable to the officer of $61,659 and $54,304, respectively. These advances are due on demand and non-interest bearing.

 

Note 12 – Concentrations

 

Concentration of Credit Risk

 

Financial instruments that potentially subject the Company to concentration of credit risk consist primarily of trade accounts receivable and cash deposits, investments and cash equivalents instruments. The Company maintains its cash in bank deposits accounts. The Company’s account at this institution is insured by the Federal Deposit Insurance Corporation (“FDIC”) up to $250,000. At February 28, 2022 and May 31, 2021, the Company held cash of approximately $178,491 and $224,395, respectively, in excess of federally insured limits. The Company has not experienced any losses in such accounts through February 28, 2022.

F-14

REVIV3 PROCARE COMPANY

CONDENSED NOTES TO UNAUDITED FINANCIAL STATEMENTS

FEBRUARY 28, 2022

 

Concentration of Revenue, Product Line, and Supplier

 

During the three months ended February 28, 2022 sales to one customer, which represented over 10% of our total sales amounted to approximately 20% of the Company’s net sales. During the nine months ended February 28, 2022 sales to two customers, which each represented over 10% of our total sales, aggregated to approximately 31% of the Company’s net sales at 15% and 16%. During the three months ended February 28, 2021 sales to one customer, which each represented over 10% of our total sales, aggregated to approximately 17% of the Company’s net sales. During the nine months ended February 28, 2021 sales to two customers, which each represented over 10% of our total sales, aggregated to approximately 41% of the Company’s net sales at 28%, and 13%.

 

During the three months ended February 28, 2022, sales to customers outside the United States represented approximately 19% which consisted of sales from Canada. During the nine months ended February 28, 2022, sales to customers outside the United States represented approximately 17% which consisted of 15% from Canada and 2% from the EU. During the three months ended February 28, 2021, sales to customers outside the United States represented approximately 35% which consisted of sales of 27% from Canada, 7% from Italy and 1% from United Kingdom during the nine months ended February 28, 2021, sales to customers outside the United States represented approximately 22% which consisted of 17% from Canada and 5% from Italy.

 

During the nine months ended February 28, 2022, sales by product line which each represented over 10% of sales consisted of approximately 16% from sale of fragrance shampoo and conditioner, 27% from sales of bundled packages, 10% from sales of prep shampoo and conditioner and 27% from sale of introductory kit (shampoo, conditioner and treatment spray). During the three months ended February 28, 2022, sales by product line which each represented over 10% of sales consisted of approximately 10% from sales of hair moisturizer and conditioner, 13% from sales of prep cleanser and shampoo, 19% from sale of introductory kit (shampoo, conditioner and treatment spray) and 42% from sale of bundled packages. During the nine months ended February 28, 2021, sales by product lines which each represented over 10% of sales consisted of approximately 35% from sale of introductory kit (shampoo, conditioner and treatment spray) and 28% from sale of fragrance shampoo and conditioner. During the three months ended February 28, 2021, sales by product lines which each represented over 10% of sales consisted of approximately 43% from sale of introductory kit (shampoo, conditioner and treatment spray), 19% from sale of prep cleanser and shampoo and 11% from sale of moisturizer and conditioner.

 

During the nine months ended February 28, sales by product line comprised of the following:

 

   For the Nine Months ended 
Hair Care Products  February 28, 2022   February 28, 2021 
Shampoos and Conditioners   86%   86%
Ancillary Products   14%   14%
Total   100%   100%

 

At February 28, 2022, accounts receivable from four customers represented approximately 91% at 10%, 22%, 18%, and 41%. At May 31, 2021, accounts receivable from four customers represented approximately 83% at 11%, 12%, 25% and 35%.

 

The Company purchased inventories and products from four vendors totaling approximately $342,310 (97% of the purchases at 10%, 23%, 30% and 34%) and three vendors totaling approximately $241,805 (84% of the purchases at 42%, 27% and 15%) during the nine months ended February 28, 2022 and 2021, respectively. The Company purchased inventories and products from three vendors totaling approximately $150,715 (94% of the purchases at 21%, 47% and 26%) and two vendors totaling approximately $180,626 (96% of the purchases at 55% and 41%) during the three months ended February 28, 2022 and 2021, respectively.

 

Note 13 – Subsequent Events

 

Subsequent to the period, on March 21, 2022, the Board adopted a stock option plan to grant 5,000,000 shares of Common Stock to officers and key employees of the corporation.

F-15

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

 

The following discussion of our financial condition and results of operations should be read in conjunction with, and is qualified in its entirety by, the condensed financial statements and notes thereto included in Item 1 in this Quarterly Report on Form 10-Q.

 

Our Management’s Discussion and Analysis contains not only statements that are historical facts, but also statements that are forward-looking.  Forward-looking statements are, by their very nature, uncertain and risky.  Forward-looking statements are often identified by words like: “believe”, “expect”, “estimate”, “anticipate”, “intend”, “project” and similar expressions, or words that, by their nature, refer to future events. You should not place undue certainty on these forward-looking statements, which apply only as of the date of this Quarterly Report on Form 10-Q. These forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from historical results or our predictions. These risks and uncertainties include international, national, and local general economic and market conditions; our ability to sustain, manage, or forecast growth; our ability to successfully make and integrate acquisitions; new product development and introduction; existing government regulations and changes in, or the failure to comply with, government regulations; adverse publicity; competition; the loss of significant customers or suppliers; fluctuations and difficulty in forecasting operating results; change in business strategy or development plans; business disruptions; the ability to attract and retain qualified personnel; the ability to protect technology; the risk of foreign currency exchange rate; and other risks that might be detailed from time to time in our filing with the Securities and Exchange Commission. Our actual results could differ materially from those discussed in the forward-looking statements. Factors that could cause or contribute to these differences include those discussed below and elsewhere in this Quarterly Report on Form 10-Q.

 

Although the forward-looking statements in this Quarterly Report reflect the good faith judgment of our management, such statements can only be based on facts and factors currently known by them. Consequently, and because forward-looking statements are inherently subject to risks and uncertainties, the actual results and outcomes may differ materially from the results and outcomes discussed in the forward-looking statements. You are urged to carefully review and consider the various disclosures made by us in herein and in our other reports as we attempt to advise interested parties of the risks and factors that may affect our business, financial condition, and results of operations and prospects.

 

Overview

 

Reviv3 Procare Company is engaged in the manufacturing, marketing, sale and distribution of professional quality hair and skin care products under various trademarks and brands. We have adopted and used the trademarks of our products for distribution throughout the United States, Canada, Europe, and Asia pursuant to the terms of twelve exclusive distribution agreements with various parties throughout our targeted market. Our manufacturing operations are outsourced and fulfilled by our co-packers and manufacturing partners. Currently, we produce seven products with sixteen separate stock-keeping units (“SKUs”) and look to expand our product lines over the next twelve months.

 

Jumpstart Our Business Startups Act of 2012 (“JOBS Act”)

 

On April 5, 2012, the Jumpstart Our Business Startups Act of 2012, or the JOBS Act, was enacted. Section 107 of the JOBS Act provides that an “emerging growth company” can take advantage of the extended transition period provided in Section 7(a)(2)(B) of the Securities Act of 1933, as amended, or the Securities Act, for complying with new or revised accounting standards. In other words, an “emerging growth company” can delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. We have irrevocably elected not to avail ourselves of this extended transition period and, as a result, we will adopt new or revised accounting standards on the relevant dates on which adoption of such standards is required for other public companies.

 

We are in the process of evaluating the benefits of relying on other exemptions and reduced reporting requirements provided by the JOBS Act. Subject to certain conditions set forth in the JOBS Act, as an “emerging growth company,” we intend to rely on certain of these exemptions from, without limitation, (i) providing an auditor’s attestation report on our system of internal controls over financial reporting pursuant to Section 404(b) of the Sarbanes-Oxley Act and (ii) complying with any requirement that may be adopted by the Public Company Accounting Oversight Board (PCAOB) regarding mandatory audit firm rotation or a supplement to the auditor’s report providing additional information about the audit and the financial statements, known as the auditor discussion and analysis. We will remain an “emerging growth company” until the earliest of (a) the last day of our fiscal year following the fifth anniversary of the closing of this offering, (b) the last day of the first fiscal year in which our annual gross revenues exceed $1.07 billion, (c) the last day of our fiscal year in which we are deemed to be a “large accelerated filer” as defined in Rule 12b-2 under the Securities Exchange Act of 1934, or Exchange Act (which would occur if the market value of our equity securities that is held by non-affiliates exceeds $700 million as of the last business day of our most recently completed second fiscal quarter), or (d) the date on which we have issued more than $1 billion in nonconvertible debt during the preceding three-year period.

-2-

Results of Operations

 

For the Nine months Ended February 28, 2022 Compared to the Nine months Ended February 28, 2021

 

Sales for the nine months ended February 28, 2022 and 2021 were $1,809,472 and $1,277,480, respectively. Sales for the nine months ended February 28, 2022 increased by $531,992 or 42% over the same comparable period in 2021, primarily due to increase in sales generated from our direct- to-consumer sales.

 

Cost of sales consisted primarily of cost of product, freight-in costs, distribution and merchant fees. Cost of sales for the nine months ended February 28, 2022 and 2021 was $611,305 and $477,578 respectively. Cost of sales as a percentage of sales for the nine months ended February 28, 2022 and 2021 was 34% and 37%, respectively. Cost of sales as a percentage of sales decreased in 2022 for the respective periods as compared to the same comparable periods in 2021 primarily due to our continued expansion in the direct sales to consumer segment, which has higher profit margins. This reduction in cost of sales was countered by higher freight in cost due to supply chain constraints.

 

Gross profit for the nine months ended February 28, 2022 and 2021 was $1,198,167 and $799,902 respectively. Gross profit as a percentage of sales for the nine months ended February 28, 2022 was 66% as compared to 63% for the same comparable period in 2021. The increase in gross profit for the nine months ended February 28, 2022 was primarily attributable to the increase sales of products in the traditionally higher margin direct to consumer segment.

 

Operating expenses consisted of marketing and selling expenses, professional and consulting fees, compensation to employees and other general and administrative expenses. Operating expenses for the nine months ended February 28, 2022 and 2021 were $1,315,379 and $934,411, respectively. Operating expenses for the nine months ended February 28, 2022 increased in amount by $380,968 or 41% over the comparable period in 2021. This increase is primarily due to increase in marketing and advertising expense to promote the Company’s product line and brand in the direct- to-consumer channels and higher shipping charges. Operating expenses as a percentage of sales for the nine months ended February 28, 2022 and 2021 remained constant at 73%.

 

Other income (expense) consisted of gain on loan forgiveness, interest income, interest expense and other finance charges. Interest income for the nine months ended February 28, 2022 and 2021 was $28 and $31, respectively. Interest expense and finance changes for the nine months ended February 28, 2022 and 2021 were $4,968 and $4,461, respectively, primarily due to interest expense related to business credit card financing charges. The Company also received $25,000 pursuant to covid relief grant fund and $10,000 as EIDL loan forgiveness.

 

As a result of the above, we reported a net loss of $87,152 compared to a net loss of $122,626 for the nine months ended February 28, 2022 and 2021, respectively.

 

For the Three months Ended February 28, 2022 Compared to the Three months Ended February 28, 2021

 

Sales for the three months ended February 28, 2022 and 2021 were $476,384 and $364,966, respectively. Sales for the three months ended February 28, 2022 increased by $111,418 or 31% over the same comparable period in 2021, primarily due to increase in sales generated from our direct to consumer and distribution sales.

-3-

Cost of sales consisted primarily of cost of product, freight-in costs, distribution and merchant fees. Cost of sales for the three months ended February 28, 2022 and 2021 was $134,609 and $93,491 respectively. Cost of sales as a percentage of sales for the three months ended February 28, 2022 and 2021 was 28% and 26%, respectively. Cost of sales as a percentage of sales increased in 2022 for the respective periods as compared to the same comparable periods in 2021. This increase in cost of sales was primarily due to increase in freight-out costs due to the increased number of shipments in the direct sales to consumer sales and higher freight in cost due to supply chain constraints.

 

Gross profit for the three months ended February 28, 2022 and 2021 was $341,775 and $271,475 respectively. Gross profit as a percentage of sales for the three months ended February 28, 2022, was 72% as compared to 74% for the same comparable period in 2021. The decrease in gross profit for the three months ended February 28, 2022 was primarily attributable to the increase in freight in cost due to supply chain constraints.

 

Operating expenses consisted of marketing and selling expenses, professional and consulting fees, compensation to employees and other general and administrative expenses. Operating expenses for the three months ended February 28, 2022 and 2021 were $439,276 and $392,503, respectively. Operating expenses for the three months ended February 28, 2022, increased in amount by $46,773 or 12% over the comparable period in 2021. This increase is primarily due to increase in marketing and advertising expense to promote the Company’s product line and brand in the direct- to-consumer channels and due to increase in delivery charges. Operating expenses as a percentage of sales for the three months ended February 28, 2022 and 2021 were 92% and 108%, respectively.

 

Other income (expense) consisted of gain on debt forgiveness, interest income, interest expense and other finance charges. Interest income for the three months ended February 28, 2022 and 2021 was $10 and $12, respectively. Interest expense and finance changes for the three months ended February 28, 2022 and 2021 were $1,823 and $1,757, respectively, primarily due to interest expense related to business credit card financing charges. The Company recognized $16,313 gain on debt forgiveness during the three months ended February 28, 2021. There was no such gain recognized for the same comparable period in the current year.

 

As a result of the above, we reported a net loss of $99,314 and $106,460 for the three months ended February 28, 2022 and 2021, respectively.

 

Liquidity and Capital Resources

 

We are an emerging growth company and currently engaged in our initial product sales and development. We have an accumulated deficit and have incurred operating losses since our inception and expect losses to continue during the fiscal year 2022. We believe our current cash balances coupled with anticipated cash flow from operating activities will be sufficient to meet our working capital requirements in the short term. We continue to control our cash expenses as a percentage of expected revenue on an annual basis and thus may use our cash balances in the short-term to invest in revenue growth. We have and will continue to generate sufficient cash for our operational needs, including any required debt payments, for at least one year from the date of issuance of the accompanying financial statements. Management is focused on growing the Company’s existing products offering, as well as its customer base, to increase its revenues. The Company cannot give assurance that it can increase its cash balances or limit its cash consumption and thus maintain sufficient cash balances for its planned operations or future acquisitions. Future business demands may lead to cash utilization at levels greater than recently experienced. We may need to raise additional capital in the future. However, the Company cannot assure that it will be able to raise additional capital on acceptable terms, or at all. Subject to the foregoing, management believes that the Company has sufficient capital and liquidity to fund its operations for at least one year from the date of issuance of the accompanying financial statements.

-4-

Cash Flows

 

Operating Activities

 

Net cash flows used in operating activities for the nine months ended February 28, 2022 was $90,873, attributable to a net loss of $87,152, depreciation of $6,603, bad debt expense of $3,012, gain on debt forgiveness of $35,000 and net change in operating assets and liabilities of $21,665 primarily due to decrease in accounts receivable and inventory, offset by a decrease in accounts payable and accrued expenses, customer deposits and an increase in prepaid expenses. Net cash flows provided by operating activities for the nine months ended February 28, 2021 was $74,212, attributable to a net loss of $122,626, gain on debt forgiveness of $16,313, depreciation of $7,622, bad debts expense of $574, stock based compensation expense of $66,400, non-cash lease expense of $1,714, and net change in operating assets and liabilities of $136,841 primarily due to a decrease in accounts receivable and increase in accounts payable, offset by an increase in inventory and prepaid expenses and other current assets and decrease in customer deposits.

 

Investing Activities

 

Net cash flows used by investing activities for the nine months ended February 28, 2022 and 2021 was $0 and $15,408 respectively, attributable to purchase of property and equipment during the nine-month period ended February 28, 2021.

 

Financing Activities

 

Net cash flows provided by financing activities for the nine months ended February 28, 2022 and 2021, amounted to $39,881 and $24,231, respectively. For the nine months ended February 28, 2022, we received $35,000 in covid relief loan funds, we received advances from a related party of $7,356 and we repaid $2,475 towards equipment financing. For the nine months ended February 28, 2021, we received advances from a related party of $20,406, proceeds from loan payable of $6,300 and repaid $2,475 towards equipment financing.

 

As a result of the activities described above, we recorded a net decrease in cash of $50,992 for the nine months ended February 28, 2022 and an increase in cash of $83,035 for the nine months ended February 28, 2021.

 

We currently have no external sources of liquidity, such as arrangements with credit institutions or off-balance sheet arrangements that will have or are reasonably likely to have a current or future effect on our financial condition or immediate access to capital.

 

We are dependent on our product sales to fund our operations and may require the sale of additional common stock to expand our operations. Our officers and directors have made no written commitments with respect to providing a source of liquidity in the form of cash advances, loans, and/or financial guarantees.

 

If we are unable to raise the funds required to fund our operations, we will seek alternative financing through other means, such as borrowings from institutions or private individuals. There can be no assurance that we will be able to raise the capital we need for our operations from the sale of our securities. We have not located any sources for these funds and may not be able to do so in the future. We expect that we will seek additional financing in the future. However, we may not be able to obtain additional capital or generate sufficient revenues to fund our operations. If we are unsuccessful at raising sufficient funds, for whatever reason, to fund our operations, we may be forced to cease operations. If we fail to raise funds, we expect that we will be required to seek protection from creditors under applicable bankruptcy laws.

 

Off-Balance Sheet Arrangements

 

We do not have any off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results or operations, liquidity, capital expenditures or capital resources that is material to investors.

-5-

Critical Accounting Policies

 

The preparation of condensed financial statements in conformity with accounting principles generally accepted in the United States of America requires us to make a number of estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements. Such estimates and assumptions affect the reported amounts of expenses during the reporting period. On an ongoing basis, we evaluate estimates and assumptions based upon historical experience and various other factors and circumstances. We believe our estimates and assumptions are reasonable in the circumstances; however, actual results may differ from these estimates under different future conditions.

 

We believe that the estimates and assumptions that are most important to the portrayal of our financial condition and results of operations, in that they require the most difficult, subjective or complex judgments, form the basis for the accounting policies deemed to be most critical to us. These critical accounting policies relate to revenue recognition, impairment of intangible assets and long-lived assets, inventory, stock compensation, and evaluation of contingencies. We believe estimates and assumptions related to these critical accounting policies are appropriate under the circumstances; however, should future events or occurrences result in unanticipated consequences, there could be a material impact on our future financial condition or results of operations.

 

Significant Accounting Policies

 

See the footnotes to our unaudited financial statements for the nine months ended February 28, 2022, included with this quarterly report.

 

Impact of COVID-19

 

For over two years, the effects of a new coronavirus (“COVID-19”) and related actions to attempt to control its spread began to impact our business. The impact of COVID-19 on our operating results for the nine months ended February 28, 2022 was limited, in all material respects, on our sales in Europe and in China where the Chinese government mandated numerous measures, including closures of businesses, limitations on movements of individuals and goods, and the imposition of other restrictive measures, in its efforts to mitigate the spread of COVID-19 within the country.

 

On March 11, 2020, the World Health Organization designated COVID-19 as a global pandemic. Governments around the world have mandated, and continue to introduce, orders to slow the transmission of the virus, including but not limited to shelter-in-place orders, quarantines, significant restrictions on travel, as well as work restrictions that prohibit many employees from going to work. Uncertainty with respect to the economic effects of the pandemic has introduced significant volatility in the financial markets.

 

To the extent that COVID-19 continues or worsens, governments may impose additional restrictions or additional governments may impose restrictions. The result of COVID-19 and those restrictions could result in a number of adverse impacts to our business, including but not limited to additional disruption to the economy and consumers’ willingness and ability to spend, temporary or permanent closures by businesses that consume our products, such as salons and spas, additional work restrictions, and supply chains being interrupted, slowed, or rendered inoperable. As a result, it may be challenging to obtain and process raw materials and supply chains to support our business needs, and individuals could become ill, quarantined, or otherwise unable to work and/or travel due to health reasons or governmental restrictions. Also, governments may impose other laws, regulations or taxes which could adversely impact our business, financial condition or results of operations. Further, if our customers’ businesses or incomes are similarly affected, they might delay or reduce purchases from us. The potential effects of COVID-19 also could impact us in a number of other ways including, but not limited to, reductions to our profitability, laws and regulations affecting our business, the availability of future borrowings, the cost of borrowings, and credit risks of our customers and counterparties.

 

Given the evolving health, economic, social, and governmental environments, the potential impact that COVID-19 could have on our business remains uncertain and could be significant.

-6-

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

 

Not required for smaller reporting companies.

 

ITEM 4. CONTROLS AND PROCEDURES

 

Disclosure Controls and Procedures

 

We maintain “disclosure controls and procedures,” as that term is defined in Rule 13a-15(e), promulgated by the SEC pursuant to the Securities Exchange Act of 1934, as amended (the “Exchange Act”). Disclosure controls and procedures include controls and procedures designed to ensure that information required to be disclosed in our reports filed under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms, and that such information is accumulated and communicated to our management, including the principal executive officer and principal financial officer, to allow timely decisions regarding required disclosure. Our management, with the participation of the principal executive officer and principal financial officer, evaluated our disclosure controls and procedures as of the end of the period covered by this quarterly report on Form 10-Q. Based on this evaluation, our principal executive officer and principal financial officer concluded that as of February 28, 2022, our disclosure controls and procedures were not effective due to material weaknesses in our internal control over financial reporting.

 

The ineffectiveness of our internal control over financial reporting was due to the following material weaknesses in our internal control over financial reporting which we identified and previously reported in the Annual Report on Form 10-K for the year ended May 31, 2021: (1) insufficient number of qualified accounting personnel governing the financial close and reporting process, (2) lack of independent directors, and (3) lack of proper segregation of duties.

 

We expect to be materially dependent upon third parties to provide us with accounting and consulting services for the foreseeable future. We believe this will be sufficient to remediate the material weaknesses related to our accounting discussed above. We plan to recruit independent directors in the near future to oversee, establish and maintain adequate internal controls over financial reporting. Until such time as we have a chief financial officer with the requisite expertise in U.S. GAAP, there are no assurances that the material weaknesses in our disclosure controls and procedures will not result in errors in our financial statements which could lead to a restatement of those financial statements. A material weakness is a deficiency or a combination of control deficiencies in internal control over financial reporting such that there is a reasonable possibility that a material misstatement of our annual or interim financial statements will not be prevented or detected on a timely basis.

 

Changes in internal control over financial reporting

 

There were no changes in our internal control over financial reporting during the quarter ended February 28, 2022 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

 

PART II - OTHER INFORMATION

 

ITEM 1. LEGAL PROCEEDINGS

 

From time to time, we may become involved in various lawsuits and legal proceedings which arise in the ordinary course of business. However, litigation is subject to inherent uncertainties and an adverse result in these or other matters may arise from time to time that may harm our business. Except as set forth below, we are currently not aware of any such pending or threatened legal proceedings or claims that we believe will have a material adverse effect on our business, financial condition or operating results.

 

On November 23, 2020, the Company was served a copy of a complaint filed by Jacksonfill, LLC in the Fourth Circuit Court for Duval County, Florida. The complaint alleges breach of Agreement for non-payments for certain products against the Company. The allegations arise from alleged discrepancies discovered by the Company in the manufacturing of certain product. The Company has retained counsel and intends to vigorously defend the allegations. The amount of the claim of $204,182 has been recorded as accounts payable, in the accompanying unaudited financial statements as of February 28, 2022.

-7-

ITEM 1A. RISK FACTORS

 

As a smaller reporting company, we are not required to provide risk factors. Please refer to our registration statement under Form S-1 for more information regarding risks related to the securities of the Company.

 

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

 

None.

 

ITEM 3. DEFAULTS UPON SENIOR SECURITIES

 

None.

 

ITEM 4. MINE SAFETY DISCLOSURES

 

Not applicable.

 

ITEM 5. OTHER INFORMATION

 

(a) Not applicable.

 

(b) During the quarter ended February 28, 2022, there have not been any material changes to the procedures by which security holders may recommend nominees to the Board of Directors.

-8-

ITEM 6. EXHIBITS

 

Exhibit       Filed 
Number   Exhibit Description   herewith
31.1   Certification of the Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.   X
31.2   Certification of the Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.   X
32.1   Certification of the Chief Executive Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.   X
32.2   Certification of the Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.   X
101.INS   XBRL Instance   X
101.SCH   XBRL Taxonomy Extension Schema   X
101.CAL   XBRL Taxonomy Extension Calculation   X
101.DEF   XBRL Taxonomy Extension Definition   X
101.LAB   XBRL Taxonomy Extension Labels   X
101.PRE   XBRL Taxonomy Extension Presentation   X

-9-

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

  REVIV3 PROCARE COMPANY
     
Date: April 11, 2022    
     
  By:  /s/ Jeff Toghraie              
    Jeff Toghraie
    Chief Executive Officer
    (Principal Executive Officer)

-10-